Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2024-05-21 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
江苏四环生物股份有限公司2023年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2023 年年度股东大会决议公告" which translates to "2023 Annual General Meeting Resolution Announcement." It details the resolutions passed at the 2023 Annual General Meeting (AGM) of 江苏四环生物股份有限公司, including voting results on various proposals such as the annual report, board work report, financial report, profit distribution plan, remuneration, and amendments to company rules. The document includes specifics about the meeting date, attendance, voting methods, and legal opinions on the meeting's validity. It is not the full annual report or financial statements but an official announcement of the AGM resolutions and voting outcomes. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is about 5,480 characters, which is sufficient for a detailed voting result announcement but not a full report. Hence, the classification is DVA with high confidence.
2024-05-21 Chinese
江苏四环生物股份有限公司公司章程（2024年5月）
Governance Information Classification · 95% confidence The document is a detailed company charter or articles of association for 江苏四环生物股份有限公司 (Jiangsu Sihuan Bioengineering Co., Ltd.). It includes comprehensive provisions on company organization, shareholder rights, share issuance, share transfer, shareholder meetings, board of directors, management, financial accounting, profit distribution, auditing, and other corporate governance matters. The content is legal and regulatory in nature, focusing on the internal rules and governance structure of the company rather than financial results, audit opinions, or meeting announcements. There is no indication that this is an annual report, audit report, earnings release, or any other financial or regulatory filing. Instead, it fits the description of a Governance Information report, which details the company's internal rules, board structure, and governance practices.
2024-05-21 Chinese
江苏四环生物股份有限公司关于股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding abnormal stock price fluctuations for the company 江苏四环生物股份有限公司 (stock code 000518). It details the stock price movement over two trading days, confirms no undisclosed material information exists, and provides risk warnings to investors. The document is short (1073 characters) and focuses on regulatory disclosure about stock trading anomalies rather than financial results, management changes, or other report types. This fits the category of a Regulatory Filing (RNS) as it is a compliance announcement related to stock trading and disclosure obligations under Shenzhen Stock Exchange rules, not a financial report or meeting material.
2024-05-09 Chinese
江苏四环生物股份有限公司2024年度日常关联交易预计公告
Regulatory Filings Classification · 95% confidence The document is a 2024 annual forecast announcement of routine related-party transactions by Jiangsu Sihuan Biological Co., Ltd. It details expected related-party transaction amounts, parties involved, pricing principles, and board and independent director approvals. The document is relatively short (3206 characters) and focuses on disclosure of anticipated related-party transactions rather than presenting comprehensive financial statements or detailed financial performance. It is an announcement of expected related-party transactions for the year, not a full financial report or audit. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and disclosures that do not fit other specific categories.
2024-04-29 Chinese
董事会对独立董事独立性评估的专项意见
Governance Information Classification · 95% confidence The document is a statement from the board of directors regarding the independence of the company's independent directors, referencing regulatory requirements and self-assessment. It does not contain financial data, audit results, or detailed management reports. It is a governance-related disclosure about board members' independence, fitting the category of Governance Information (CGR). The document length is short and focused on governance compliance rather than financial or operational reporting.
2024-04-29 Chinese
江苏四环生物股份有限公司独立董事2023年度述职报告（王莉）
Board/Management Information Classification · 95% confidence The document is titled as the "2023年度独立董事述职报告" which translates to "2023 Annual Independent Director's Work Report". It details the independent director's background, independence statement, attendance at board meetings, committee participation, and efforts to protect shareholder rights during the year 2023. The content is a narrative report on the independent director's duties and activities rather than a financial report or announcement. It is not an annual report, audit report, earnings release, or any other financial filing. It is a management-related report focusing on board and governance activities, specifically the independent director's report on their duties and performance. This fits best under Board/Management Information (MANG) as it relates to board member activities and governance roles. The document length is 2509 characters, which is relatively short but contains substantive content about the independent director's work, not just an announcement or certification. Therefore, the classification is MANG with high confidence.
2024-04-29 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.